Therapeutic area strategy
Major global biopharma evaluating overall TA strategy
Commercial and R&D leadership for a TA of a large biopharma wanted to grow pipeline by pursuing an expanded set of diseases. There was general awareness of a plethora of novel science and early research activity in areas adjacent to their current pipeline and marketed products, but was seeking guidance on the diseases with the strongest potential to add to their TA strategy.
Disease area analysis and mapping
Developed a brief prioritization exercise to identify disease areas of greatest interest, followed by a deep-dive in prioritized areas. Diseases ranged from rare to broad, with a full assessment of biology and clinical experience from research through Phase 3. Analysis was supplemented by a visualization tool that enabled efficient communication of findings to stakeholders across the organization.
Disease framework adopted across organization, analysis enabled new TA strategy
The analysis identified areas of “white space” for the company to pursue, which enabled an update to the TA strategy and ultimately several in-licensing deals to bolster the pipeline. Additionally, the approach was adopted by other therapeutic areas to facilitate further strategic reviews internally.